Indication
diastolic
8 clinical trials
7 products
1 drug
Clinical trial
Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart FailureStatus: Recruiting, Estimated PCD: 2026-12-31
Product
NAN-101Clinical trial
A Phase 1b, Pilot Trial Evaluating the Safety and Pharmacodynamic Effects of SRD-001 (AAV1-SERCA2a) in Subjects With Heart Failure With Preserved Ejection FractionStatus: Recruiting, Estimated PCD: 2025-08-01
Product
AAV1/SERCA2aClinical trial
Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection FractionStatus: Completed, Estimated PCD: 2023-09-20
Product
EmpagliflozinClinical trial
The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart FailureStatus: Terminated, Estimated PCD: 2023-01-11
Product
ErtugliflozinProduct
PlaceboClinical trial
N-of-1 Trials for Deprescribing Beta-blockers in HFpEFStatus: Completed, Estimated PCD: 2023-04-28
Drug
Beta blockersClinical trial
Regress-HFpEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCsStatus: Completed, Estimated PCD: 2023-04-28
Product
Allogeneic Derived CellsClinical trial
N-of-1 Trials for Deprescribing Beta-blockers in HFpEFStatus: Completed, Estimated PCD: 2022-04-28
Clinical trial
A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication OptimizationStatus: Recruiting, Estimated PCD: 2026-07-01
Product
Beta blocker